While there have been a variety of preclinical studies regarding the effects of HDAC inhibitors specifically in glioblastoma, one of the most interesting effects is alteration of the tumor itself to increase tumor susceptibility to antitumor immune attack. This evidence concerns the gene HDAC9 and neoplasm.